BioCorRx Inc. (OTC: BICX), a developer of treatment support programs for substance use disorders, announced on September 10, 2026, the appointment of Richard J. Baum to its Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President's Commission on Combating Drug Addiction and the Opioid Crisis. His nearly three decades of federal drug policy experience, including 28 years at ONDCP across six presidential administrations, positions him as a significant addition for a company seeking to bridge policy and treatment access.
The appointment matters because BioCorRx is at a critical juncture in advancing both its treatment programs and pharmaceutical pipeline. The company's subsidiary, BioCorRx Pharmaceuticals Inc., focuses on commercialization and development, including LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, and BICX104, an investigational biodegradable naltrexone implant technology. Baum's expertise in treatment and recovery policy, prevention, public safety, and interagency coordination is expected to support BioCorRx's engagement with treatment and recovery organizations, public health agencies, healthcare systems, justice-system partners, and policymakers.
In a statement, Lourdes Felix, Chief Executive Officer of BioCorRx Inc., said, "Rich has spent his career at the intersection of drug policy, public health, treatment, and public safety, and we are honored to welcome him to BioCorRx. His deep understanding of how policy translates into real-world treatment access will be invaluable as we work to expand awareness of evidence-based approaches to addiction treatment and thoughtfully position our programs within the broader continuum of care."
Baum commented, "I am pleased to join BioCorRx as a strategic advisor at a time when the country continues to face significant challenges related to opioid use, addiction treatment, and recovery. BioCorRx is working across several important points in the treatment continuum, including managing opioid withdrawal symptoms with LUCEMYRA. In an era of increasingly dangerous polysubstance use, particularly involving illicit fentanyl and methamphetamine, I am also encouraged by the Company's research evaluating BICX104, an investigational long-duration naltrexone implantable pellet, as a potential treatment for methamphetamine use disorder. I look forward to helping BioCorRx position these approaches within a comprehensive, evidence-based system of care that expands treatment access, supports retention, and improves long-term recovery."
Baum's background includes serving as an Adjunct Professor at Georgetown University's McCourt School of Public Policy and authoring Inside America's Opioid Crisis: 12 Hard Lessons for Today's Drug War. He also serves on the United Against Fentanyl Board of Directors. His work focuses on improving addiction treatment and recovery, strengthening public health and public safety collaboration, and developing more effective responses to opioid, synthetic-drug, and polysubstance-use threats. His recent writing on the opioid crisis has appeared in The Lancet.
The implications of this appointment extend beyond BioCorRx's immediate operations. With Baum's guidance, the company may be better positioned to navigate the complex regulatory and policy landscape surrounding addiction treatment. His experience with national drug control strategies could help BioCorRx advocate for policies that support broader access to medications like LUCEMYRA and investigational treatments like BICX104. Additionally, his network across federal, state, and local agencies could facilitate partnerships that enhance the company's reach and credibility.
BioCorRx's treatment programs include Beat Addiction Recovery, a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app and medication prescribed by an independent treating physician at their discretion. The company also offers the UnCraveRx® Weight Loss Program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. For more information on UnCraveRx®, visit https://www.uncraverx.com. For more information on BioCorRx and its subsidiary pipeline, visit https://www.BioCorRx.com.
The ongoing clinical study of BICX104 is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), with additional studies planned. A prior clinical study evaluating the Company's implant technology was completed in 2023 (ClinicalTrials.gov Identifier: NCT04828694).
As the opioid crisis persists—with an estimated 4.0 million people in the United States aged 12 or older having an opioid use disorder in the past year, according to the 2025 National Survey on Drug Use and Health—BioCorRx's efforts to expand treatment options are timely. Methamphetamine use disorder also remains a serious public health concern, with approximately 2.7 million people reporting past-year use. Baum's advisory role could help BioCorRx address these challenges through a comprehensive, evidence-based approach.
